Tumor Biology

, Volume 36, Issue 8, pp 6045–6051 | Cite as

The platelet-to-lymphocyte ratio predicts poor survival in patients with huge hepatocellular carcinoma that received transarterial chemoembolization

  • Tong-Chun Xue
  • Qing-An Jia
  • Ning-Ling Ge
  • Bo-Heng Zhang
  • Yan-Hong Wang
  • Zheng-Gang Ren
  • Sheng-Long Ye
Research Article


Inflammation is particularly strong in huge hepatocellular carcinoma (HCC). However, it is unclear whether the platelet-to-lymphocyte ratio (PLR), as an inflammatory-related marker, can predict survival of patients with huge HCC. In this study, we enrolled 291 patients with huge HCC (diameter over 10 cm) who were undergoing repeated transarterial chemoembolization (TACE) at our institute. The baseline PLR was calculated from complete serum blood counts before the first chemoembolization. We found that a baseline PLR cutoff value over 150 best predicted huge HCC survival. The 12, 24, and 36 months survival rates in the high PLR group (22.6, 8.1, and 4.1 %, respectively) were significantly lower than in the low PLR group (35.6, 22.4, and 14 %, respectively). Thus, a significant difference was found in overall survival (log–rank test, p < 0.0001). Univariate analyses indicated a high PLR (p < 0.0001) was predictor of poor survival, and multivariate Cox analyses further showed that a high PLR (p = 0.002) was an independent factor that predicted worse survival. In conclusion, for patients with huge HCC, a high baseline PLR is a useful predictor of poor survival in patients undergoing chemoembolization. Additional anti-inflammatory or anti-platelet treatments, in combination with TACE, may improve survival in HCC patients with high PLR.


Platelets Lymphocytes Huge hepatocellular carcinoma Chemoembolization Inflammation 



This study was supported by the State Key Project on Infectious Diseases of China (No. 2012ZX10002-016).


  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Tang ZY, Zhou XD, Ma ZC, Wu ZQ, Fan J, Qin LX, et al. Downstaging followed by resection plays a role in improving prognosis of unresectable hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2004;3:495–8.PubMedGoogle Scholar
  3. 3.
    Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:187–96.CrossRefPubMedGoogle Scholar
  4. 4.
    Kim KH, Kim MS, Chang JS, Han KH. Kim do Y, Seong J: Therapeutic benefit of radiotherapy in huge (>/=10 cm) unresectable hepatocellular carcinoma. Liver Int. 2014;34:784–94.CrossRefPubMedGoogle Scholar
  5. 5.
    Ariizumi S, Kotera Y, Takahashi Y, Katagiri S, Yamamoto M. Impact of hepatectomy for huge solitary hepatocellular carcinoma. J Surg Oncol. 2013;107:408–13.CrossRefPubMedGoogle Scholar
  6. 6.
    Shi M, Chen JA, Lin XJ, Guo RP, Yuan YF, Chen MS, et al. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern china. World J Gastroenterol. 2010;16:264–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Zhao Y, Wang WJ, Guan S, Li HL, Xu RC, Wu JB, et al. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann Oncol. 2013;24:1786–92.CrossRefPubMedGoogle Scholar
  8. 8.
    Yoon HM, Kim JH, Kim EJ, Gwon DI, Ko GY, Ko HK. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort. J Vasc Interv Radiol. 2013;24:1639–46.CrossRefPubMedGoogle Scholar
  9. 9.
    Wirth TC. Spontaneous and therapeutic immune responses in hepatocellular carcinoma: implications for current and future immunotherapies. Expert Rev Gastroenterol Hepatol. 2014;8:101–10.CrossRefPubMedGoogle Scholar
  10. 10.
    Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–71.CrossRefPubMedGoogle Scholar
  11. 11.
    Alison MR, Nicholson LJ, Lin WR. Chronic inflammation and hepatocellular carcinoma. Recent Results Cancer Res. 2011;185:135–48.CrossRefPubMedGoogle Scholar
  12. 12.
    Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, et al. Chronic inflammation associated with hepatitis c virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology. 2007;46:48–57.CrossRefPubMedGoogle Scholar
  13. 13.
    Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:1204–12.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang D, Wu M, Feng FZ, Huang HF, Yang JX, Shen K, et al. Pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios do not predict survival in patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy. Chin Med J (Engl). 2013;126:1464–8.Google Scholar
  15. 15.
    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.CrossRefPubMedGoogle Scholar
  16. 16.
    Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. 2012;23:265–73.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Krenn-Pilko S, Langsenlehner U, Thurner EM, Stojakovic T, Pichler M, Gerger A, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer. 2014;110:2524–30.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Liu H, Wu Y, Wang Z, Yao Y, Chen F, Zhang H, et al. Pretreatment platelet-to-lymphocyte ratio (plr) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer. J Thorac Dis. 2013;5:783–9.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Lai Q, Castro Santa E, Rico Juri JM, Pinheiro RS, Lerut J. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int. 2014;27:32–41.CrossRefPubMedGoogle Scholar
  20. 20.
    Riedl J, Pabinger I, Ay C. Platelets in cancer and thrombosis. Hamostaseologie. 2014;34:54–62.CrossRefPubMedGoogle Scholar
  21. 21.
    Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11:123–34.CrossRefPubMedGoogle Scholar
  22. 22.
    Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–94.CrossRefPubMedGoogle Scholar
  23. 23.
    Palumbo JS, Degen JL. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb Res. 2007;120 Suppl 2:S22–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via p2y2 receptor. Cancer Cell. 2013;24:130–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576–90.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Xue TC, Zhang L, Xie XY, Ge NL, Li LX, Zhang BH, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio in primary liver cancer: a meta-analysis. PLoS ONE. 2014;9:e96072.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Li X, Chen ZH, Ma XK, Chen J, Wu DH, Lin Q, Dong M, Wei L, Wang TT, Ruan DY, Lin ZX, Xing YF, Deng Y, Wu XY, Wen JY. Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumour Biol. 2014.Google Scholar
  28. 28.
    Turkmen K, Erdur FM, Ozcicek F, Ozcicek A, Akbas EM, Ozbicer A, et al. Platelet-to-lymphocyte ratio better predicts inflammation than neutrophil-to-lymphocyte ratio in end-stage renal disease patients. Hemodial Int. 2013;17:391–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Neofytou K, Smyth EC, Giakoustidis A, Khan AZ, Cunningham D, Mudan S. Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Med Oncol. 2014;31:239.CrossRefPubMedGoogle Scholar
  30. 30.
    Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer. 2013;109:401–7.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Parisi I, Tsochatzis E, Wijewantha H, Rodriguez-Peralvarez M, De Luca L, Manousou P, et al. Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria. Liver Transpl. 2014;20:1327–35.CrossRefPubMedGoogle Scholar
  32. 32.
    Hossain MA, Kim DH, Jang JY, Kang YJ, Yoon JH, Moon JO, et al. Aspirin induces apoptosis in vitro and inhibits tumor growth of human hepatocellular carcinoma cells in a nude mouse xenograft model. Int J Oncol. 2012;40:1298–304.PubMedGoogle Scholar
  33. 33.
    Kim JH, Chang JH, Rhee KH, Yoon JH, Kwon SH, Song K, et al. Cyclooxygenase inhibitors induce apoptosis in sinonasal cancer cells by increased expression of nonsteroidal anti-inflammatory drug-activated gene. Int J Cancer. 2008;122:1765–73.CrossRefPubMedGoogle Scholar
  34. 34.
    Protasiewicz M, Szymkiewicz P, Kuliczkowski W, Mysiak A, Witkiewicz W. Modern antiplatelet therapy—opportunities and risks. Adv Clin Exp Med. 2013;22:875–85.PubMedGoogle Scholar
  35. 35.
    Li J, Jian Z, Song M, Guo W, Chen G, Lu W, et al. Tailored antiplatelet therapy and clinical adverse outcomes. Heart. 2014;100:41–6.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Tong-Chun Xue
    • 1
    • 2
  • Qing-An Jia
    • 3
  • Ning-Ling Ge
    • 1
    • 2
  • Bo-Heng Zhang
    • 1
    • 2
    • 4
  • Yan-Hong Wang
    • 1
    • 2
  • Zheng-Gang Ren
    • 1
    • 2
  • Sheng-Long Ye
    • 1
    • 2
  1. 1.Liver Cancer Institute, Zhongshan HospitalFudan UniversityShanghaiPeople’s Republic of China
  2. 2.Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of EducationFudan UniversityShanghaiPeople’s Republic of China
  3. 3.Institutes of Biomedical SciencesFudan UniversityShanghaiPeople’s Republic of China
  4. 4.Department of Medical Statistics, Zhongshan HospitalFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations